BOSTON, Feb. 25, 2016 /PRNewswire/ -- Paxeramed Corp.- a leading developer and supplier of innovative medical imaging and patient engagement solutions with a mission to make medical records available to patients through a single app, has announced the release of version 2.0 of its patient engagement app - CarePassport, the company will highlight the major update at HIMSS – Las Vegas from Feb 29th –Mar 3rd 2016.
CarePassport - a next generation patient engagement app, provides patients with a single-point to aggregate, store, share and manage their health data. The solution is now available for download in the App Store and on Google Play for both Apple and Android devices at no cost to consumers.
Only about 20% of U.S. adults currently have access to their medical records online and 41% of U.S. consumers would be willing to switch doctors to gain online access to their own electronic medical records. A robust, one-point patient app is necessary to enable patients to have easy access to their health information and better support patients through-out their medical journey,
CarePassport is designed to engage users to take a more active role in their care and significantly improves patient satisfaction, outcomes and health service efficiency. The universal patient engagement app enables users to view their care teams contact info, communicate with them via secure messaging and request, change or cancel appointments. Patients can also view their medical images, lab and clinical reports, and share healthcare information securely with their healthcare providers.
The latest version further simplifies the patient experience by allowing users to complete and submit registration forms before arriving to the healthcare facility. Patients may view the facility location using Google Maps and request an Uber from within the app. Upon arrival to the facility, patients will be able to check-in from the app interface using a QR code, which will significantly streamline the check-in process and enhance the patient experience.
Healthcare providers version of the app, CarePassport-MD, allows caregivers to build quality relationships with patients and increases revenue through fostering patient retention and loyalty. CarePassport-MD features a dashboard that indexes the data content to be easily searched and mined. The advanced dashboard facilitates tracking of the vast amounts of intraoperative data and correlating that data with patients' outcomes. This allows healthcare providers to analyze patients' data, set medical and follow-up notifications, enable patient behavioral detection, and monitor patient risk categories, thus improving treatment.
"CarePassport has proved to be a disruptive technology as it truly addresses all of the communications challenges patients and healthcare providers face today," said Dr. Shoura, founder of Paxeramed Corp. - The developer of the platform. "The App provides patients with a complete view of their medical data provided to them across multiple providers - hospitals, physician practices and from their wearables, and enables users to engage more proactively and meaningfully with their healthcare providers," Dr. Shoura added.
CarePassport's back-end is designed to run as a stand-alone solution or seamlessly integrates with existing EMR systems to help streamline administrative routine tasks including scheduling appointments, registration, and patient reminders.
Paxeramed Corp™ is a premier global medical imaging and patient engagement solution
s developer based in Boston, MA. The company is on a mission to transform healthcare by empowering patients to take a more active role in their care and significantly improves patient satisfaction, enhance outcomes and advance health service efficiency with its universal patient app, CarePassport, available on the App Store, Google Play, and on CarePassport.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/paxeramed-announces-release-of-carepassport---version-20-a-major-update-of-the-best-in-class-patient-engagement-app-300226128.html
SOURCE Paxeramed Corp.